The Medical and Surgical Practice of NaProTECHNOLOGY, 369-380, 2004
Chapter 30: Postpartum Depression: Evaluation and Treatment
Author affiliations
- Pope Paul VI Institute for the Study of Human Reproduction, Omaha, Nebraska. ROR
The Medical and Surgical Practice of NaProTECHNOLOGY, 369-380, 2004
Postpartum depression in susceptible women is linked to abrupt postpartum progesterone withdrawal following the high-progesterone state of pregnancy, particularly in those with prior PMS, luteal phase defects, or recurrent miscarriage, and NaProTECHNOLOGY evaluates this through serum progesterone, thyroid function, and prolactin assessment in the postpartum period. Treatment uses bioidentical progesterone -- preferably intramuscular for reliable absorption -- with serum levels monitored every two weeks for dose titration, and once cycles resume, dosing is resynchronized to the CrMS Peak day; Hilgers reports no increase in congenital anomalies in over 2,000 progesterone-supported pregnancies in the Pope Paul VI Institute series.
Hilgers, T. W. (2004). Chapter 30: Postpartum Depression: Evaluation and Treatment. *The Medical and Surgical Practice of NaProTECHNOLOGY*, 369-380.
Hilgers TW. Chapter 30: Postpartum Depression: Evaluation and Treatment. The Medical and Surgical Practice of NaProTECHNOLOGY. 2004:369-380.
Hilgers, T. W. "Chapter 30: Postpartum Depression: Evaluation and Treatment." *The Medical and Surgical Practice of NaProTECHNOLOGY*, 2004, pp. 369-380.